Clinical Trials Directory

A Phase II Trial of Dasatinib in Patients With Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas

The purpose of this study is to determine whether patients with melanoma will benefit from dasatinib. Patients with the following types of melanoma can be enrolled in this study: acral melanomas (those that occur on the palms, soles, or underneath the fingernails), mucosal melanomas (those that occur on surfaces of the body such as the mouth, sinuses, rectum or vagina), and skin melanomas which have evidence of chronic sun damage. Dasatinib is not chemotherapy and is an oral medication which targets proteins that are thought to be present on the melanoma cells.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : dasatinib
  • other : laboratory biomarker analysis

Phase: Phase 2

Eligibility

Ages Eligible For Study:

18 Years - N/A

External Links

Explore related trials

Contact information

Primary Contact:

Jennifer Wong 650-723-1002

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: